Drugs / DT-9081
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05582850 | Nov 2022 → Apr 2025 | cancer | Domain Therapeutics SA | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-04-30 | Domain Therapeutics SA | Results Domain Therapeutics Presents Novel Data Addressing Key Challenges in Oncology at AACR 2025 domaintherapeutics.com ↗
Phase I clinical results of DT-9081, an EP4 receptor antagonist, allowed selection of recommended Phase II dose (RP2D) for further development in solid tumors |
| 2025-04-01 | Domain Therapeutics SA | Results Domain Therapeutics to Present Data on its GPCR Lead Programs at AACR Annual Meeting 2025 domaintherapeutics.com ↗
Interim Phase I results demonstrate DT-9081’s favorable safety profile, linear pharmacokinetics, and dose-dependent inhibition of EP4R signaling, with data supporting the recommended Phase II dose ( RP2D ). |
| 2022-11-10 | Domain Therapeutics SA | Results Domain Therapeutics presents new data on its EP4R and CCR8 antagonists at 2022 SITC Annual Meeting domaintherapeutics.com ↗
The preclinical data being presented on Domain’s immuno-oncology candidate, DT-9081, shows that the drug candidate was able to demonstrate strong anti-tumor effects in two cancer models with notable synergies with immune checkpoint inhibitors to induce long lasting complete responses. |
| 2022-10-19 | Domain Therapeutics SA | Regulatory Domain Therapeutics to progress into clinical trials with its EP4R antagonist DT-9081 in solid tumors domaintherapeutics.com ↗
Domain Therapeutics (“Domain” or “the Company”), a drug discovery and development company focused on G Protein-Coupled Receptors (GPCRs) in immuno-oncology (IO), today announces that its proprietary IO candidate, DT-9081, has cleared its clinical trial applications (CTA) by the ANSM (Agence Nationale de Sécurité du Médicament et des produits de santé) in France and the AFMPS (Agence Fédérale des Médicaments et des Produits de Santé) in Belgium, enabling Domain to start its Phase I clinical trial. |
All press releases naming this drug 6 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DT-9081 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05582850 ↗ |
| Route | Oral | “Patients will be dosed orally once daily.” NCT05582850 ↗ |